CoChat

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment

Open access
Bronte, Enrico, Bronte, Giuseppe, Novo, Giuseppina, Bronte, Fabrizio, Bavetta, Maria Grazia, Re, Giuseppe Lo, Brancatelli, Giuseppe, Bazan, Viviana, Natoli, Clara, Novo, Salvatore, Russo, Antonio · 2015 · Oncotarget
Cited by 64

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

// Enrico Bronte 1,* , Giuseppe Bronte 1,* , Giuseppina Novo 2,* , Fabrizio Bronte 3 , Maria Grazia Bavetta 3 , Giuseppe Lo Re 4 , Giuseppe Brancatelli 4 , Viviana Bazan 1 , Clara Natoli 5 , Salvatore Novo 2 and Antonio Russo 1 1 Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy 2 Department of Internal Medicine and Cardiovascular Disease, University of Palermo, Palermo, Italy 3 DiBiMIS, Section of Gastroenterology, University of Palermo, Palermo, Italy 4 Department of Radiology, University of Palermo, Palermo, Italy 5 Department of Medical, Oral and Biotechnological Sciences, University “G. D’Annunzio”, Chieti, Italy * These authors contributed equally to this work Correspondence to: Antonio Russo, email: // Keywords : B-RAF, B-RAF inhibitors, cardio-oncology, cardiotoxicity, dabrafenib Received : August 04, 2015 Accepted : August 22, 2015 Published : September 28, 2015 Abstract The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolongation. Though this cardiovascular side effect is not common using these drugs, it must be noticed early and recognize its signals. Indeed, Oncologists and Cardiologists should work in cooperation to prevent lethal events, such as fatal arrhythmias or sudden cardiac death. These events could originate from an uncontrolled QT prolongation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.5853

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 64

Metadata

Authors
Bronte, E., Bronte, G., Novo, G., Bronte, F., Bavetta, M. G., Re, G. L., Brancatelli, G., Bazan, V., Natoli, C., Novo, S., & Russo, A.
Venue
Oncotarget
Published
2015-09-28
Volume
6
Issue
34
Pages
35589-35601
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2228476560
Cited by
64
References
10
FWCI
5.35
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.